Announced Date: 2024-05-21 (May 21, 2024)<\/p>\n\n\n\n
Seller: ProfoundBio (China)<\/p>\n\n\n\n
Buyer: \u00a0Genmab A\/S (Denmark)<\/p>\n\n\n\n
Payment: USD 1.8 billion in cash<\/p>\n\n\n\n
.<\/p>\n\n\n\n
Key Assets: Three candidates in clinical development, including rinatabart sesutecan (Rina-S), plus ProfoundBio\u2019s novel antibody-drug conjugate technology platforms.<\/p>\n\n\n\n
Lead Asset: Rinatabart sesutecan (Rina-S, GEN1184, PRO1184)<\/p>\n\n\n\n
Asset Modality and Target: FR\u03b1-targeted, Topo1 ADC<\/p>\n\n\n\n
Potential Indication: \u00a0Treatment of ovarian cancer and other FR\u03b1-expressing solid tumors<\/p>\n\n\n\n
Current Stage: \u00a0Phase 1\/2 clinical trial<\/p>\n\n\n\n
. <\/p>\n\n\n\n
About ProfoundBio
ProfoundBio is a clinical-stage biotechnology company focused on the development of novel antibody-based therapeutics for patients with cancer. Built on internally developed, innovative, and proprietary technology platforms, ProfoundBio has developed a pipeline consisting of multiple ADC drug candidates targeting solid tumors and hematological malignancies. <\/p>\n\n\n\n
The company’s disclosed development pipeline consists of rinatabart sesutecan (Rina-S; PRO1184), an ADC targeting FR\u03b1; PRO1160, an ADC targeting CD70; PRO1107, an ADC targeting PTK7; and PRO1286, a bispecific ADC targeting EGFR and cMET. ProfoundBio is headquartered in Seattle, Washington with an R&D center of innovation in Suzhou, China.<\/p>\n\n\n\n
.<\/p>\n\n\n\n
Link:<\/p>\n\n\n\n
. Genmab Completes Acquisition of ProfoundBio – Genmab A\/S<\/a><\/p>\n\n\n\n